Hospira Recalls 2 Lots of Bupivacaine
Both may contain dangerous particulates.
Published: September 16, 2013
Hospira is recalling 2 lots of Bupivacaine HCl Injection that were found by customers to have particulate floating and/or embedded in the glass vials:
- Lot 18-136-DK (expires 6/1/14) of 0.25% (2.5 mg/mL) was found to contain stainless steel ranging in size from 542 microns to 1700 microns.
- Lot 23-338-DK (expires 11/1/14) of 0.75% (7.5 mg/mL) was found to contain iron oxide with an average size of 2000 microns.
Both lots were sold in cartons of 25 units, with 50 units per case, in glass tear-top vials. Lot 18-136-DK was distributed in August and September 2012; Lot 23-338-DK was distributed between January and May 2013. Both were distributed nationwide to wholesalers/distributors, hospitals and pharmacies.
Hospira says it hasn't received any reports of adverse events, but warns that injecting foreign particulates may cause thrombophlebitis, bacteremia, sepsis, and/or endocarditis, and may be fatal. Signs and symptoms can include redness, pain, swelling at the site, fever, shortness of breath, tachycardia, nausea and vomiting.
If you have questions, call 866-240-5364 (Lot 18-136-DK) or 888-627-2279 (Lot 23-338-DK).
© Copyright Herrin Publishing Partners LP. REPRODUCTION OF THIS COPYRIGHTED CONTENT IS STRICTLY PROHIBITED. We encourage LINKING to this content; view our linking policy here.
Also in the News...
Are Younger Surgeons Less Prepared?
$30 Million Malpractice Award to Woman Left Speechless by Surgical Fire
Second Victim Dies from ASC Attack
Robots Recall: Da Vinci Warns Customers Arms Can Stall
Can You Trust Your Biological Indicators?
Nurse at Texas ASC Stabbed to Death
CareFusion to Buy GE Healthcare's Vital Signs Division